Get started
Author

Ciara Freeman

Observed institution: Moffitt Cancer Center
OpenAlex ID: A5148654466
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium
2026 · Andrew J. Portuguese, James A. Davis, et al. · Blood Cancer Journal · 7
PDF
PA-004 A Modular AI Framework Generates Interpretable, Multi-modal Analysis Pipelines to Support Translational Research for Multiple Myeloma
2026 · Ariosto Silva, Kenneth Shain, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-397 Real-World Experience with Early-Line Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma
2026 · Brandon Kale, Ariel Grajales-Cruz, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-520 Usage of Prophylactic Dexamethasone to Reduce Incidence and Severity of Toxicity after Ciltacabtagene Autoleucel
2026 · Logan S. Dugas, Eric Gaskill, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CT-1538: Impact of Preexisting Anxiety and Depression on Toxicity and Outcomes After Axicabtagene Ciloleucel for Patients With Diffuse Large B-Cell Lymphoma
2026 · Syed Hussain, Laith Hamed, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-1252: Real-World Outcomes of Talquetamab in MonumenTAL-1 Trial–Ineligible Versus Trial-Eligible Patients With Relapsed/Refractory Multiple Myeloma
2026 · Juan Ramirez, Rida Darji, et al. · Clinical Lymphoma Myeloma & Leukemia
CT-1541: Impact of Preexisting Cognitive Impairments on Toxicity and Outcomes After Axicabtagene Ciloleucel for Patients With Diffuse Large B-Cell Lymphoma
2026 · Laith Hamed, Syed Hussain, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-1330: Prophylactic Tocilizumab to Reduce the Risk of CRS and ICANS in Patients With Relapsed/Refractory Multiple Myeloma Treated With Elranatamab
2026 · Corbin Wright, Rida Darji, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-744: Nonrelapse Mortality Across Anito-cel and Other BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis
2026 · Peter Forsberg, Aaron Rosenberg, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1330: Prophylactic Tocilizumab to Reduce the Risk of CRS and ICANS in Patients With Relapsed/Refractory Multiple Myeloma Treated With Elranatamab
2026 · Corbin Wright, Rida Darji, et al. · Clinical Lymphoma Myeloma & Leukemia
CT-1538: Impact of Preexisting Anxiety and Depression on Toxicity and Outcomes After Axicabtagene Ciloleucel for Patients With Diffuse Large B-Cell Lymphoma
2026 · Syed Hussain, Laith Hamed, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CT-1541: Impact of Preexisting Cognitive Impairments on Toxicity and Outcomes After Axicabtagene Ciloleucel for Patients With Diffuse Large B-Cell Lymphoma
2026 · Laith Hamed, Syed Hussain, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-744: Nonrelapse Mortality Across Anito-cel and Other BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma: A Systematic Reviewand Meta-Analysis
2026 · Peter Forsberg, Aaron Rosenberg, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1252: Real-World Outcomes of Talquetamab in MonumenTAL-1 Trial–Ineligible Versus Trial-Eligible Patients With Relapsed/Refractory Multiple Myeloma
2026 · Juan Ramirez, Rida Darji, et al. · Clinical Lymphoma Myeloma & Leukemia
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
2026 · Aimaz Afrough, Oren Pasvolsky, et al. · Blood Cancer Journal
PDF
The Safety and Efficacy of Commercial BCMA‐Directed CAR T‐Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma
2026 · Matthew J. Rees, Raffaella Cassano Cassano, et al. · American Journal of Hematology
Works count: 16
Citation count: 7
H-index: 1
I10-index:
Year
Topic
Type